1 The impact of early anti-SARS-CoV-2 antibody production on the length of

2 hospitalization stay among COVID-19 patients.

3

Dalziza Victalina de Almeida 1*, Priscila Alves Cezar 1, Thais Freitas Barreto Fernandes 4 ¹, Marcos Gustavo Araujo Schwarz ², Leila Mendonca-Lima ², Carmem Beatriz Wagner 5 Giacoia-Gripp¹, Fernanda Heloise Côrtes¹, Monick Lindenmeyer Guimarães¹, Jose 6 Henrique Pilotto ¹, Nathalia Beatriz Ramos de Sá ¹, Andressa da Silva Cazote ¹, Larissa 7 Rodrigues Gomes ³, Marcel de Souza Borges Quintana ⁴, Marcelo Ribeiro-Alves ⁵, Lara 8 Coelho ⁵, Kim Mattos Geraldo ⁵, Maria Pia Diniz Ribeiro ⁵, Sandra Wagner Cardoso ⁵, 9 Beatriz Gilda Jegerhom Grinsztejn ⁵, Valdiléa Gonçalves Veloso dos Santos ⁵, Mariza 10 Gonçalves Morgado 1 11 12 13 1 Laboratory of AIDS & Molecular Immunology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil. 14 15 2 Laboratory of Functional Genomics and Bioinformatics, Instituto Oswaldo Cruz, 16 Fiocruz, Rio de Janeiro, Brazil. 17 18 3 Center of Technological Development in Health (CDTS)/National Institute of Science 19 and Technological for Innovation on Neglected population diseases (INCT-IDPN), 20 21 FIOCRUZ, Rio de Janeiro 22 23 4 Clinical Research Platform, Evandro Chagas National Institute of Infectious Diseases, 24 FIOCRUZ, Rio de Janeiro, RJ, Brazil 25 26 5 Laboratory of Clinical Research on STD/AIDS, National Institute of Infectology Evandro Chagas, FIO-CRUZ, Rio de Janeiro 27 28 29 *Correspondence: Dalziza Victalina de Almeida - Address: Laboratory of AIDS & Molecular Immunology, Oswaldo Cruz Institute, FIOCRUZ. Av. Brazil 4365, Leonidas 30 Deane Building, Room 401, Rio de Janeiro, Brazil. 21040-360 - E-mail: 31 dalziza@gmail.com Tel: +55-21-38658227 - Fax: +55-21-38658173. 32 33 34 Abstract: COVID-19 has challenged the scientific community in the search for biological 35 markers and information that can contribute to the early management of the 36 severe disease. Given the global scale of COVID-19, including reports of 37 reinfection even in the presence of effective vaccines, we have not yet been able 38 39 NOTO: Etiadicate the disease that is factor intified the einergender of new wave signation.

increasing number of hospitalizations. This study aimed to characterize the 40 neutralizing antibody (Nab) geometric mean titers (GMTs) in hospitalized patients 41 with COVID-19 and to evaluate the association with length of stay, comorbidities, 42 and patient outcome. Among the 103 participants, 84 (81.5%) had some previous 43 condition associated with worsening health, and 31 (30%) died. We found that 44 neutralization potency varied greatly across individuals and was significantly 45 higher in patients discharged before 14 days than in patients who stayed longer 46 in the hospital. During the study period, 15 people living with HIV (PLWH) were 47 hospitalized, and no significant difference in clinical characteristics or anti-SARS-48 CoV-2 Nabs was observed. However, PLWH with severe COVID-19 were 49 younger (41.7, IQR=17.5) than other hospitalized COVID-19 patients (59.3, 50 IQR=22, P < 0.01). A high anti-HIV-1 antibody GMT of 583.9 (95% CI: 344-990) 51 52 was detected, demonstrating maintenance of anti-HIV-1 Nab production among PLWH coinfected with SARS-CoV-2. Therefore, these results indicate that 53 neutralizing antibodies are not the only immunological response capable of 54 controlling disease progression. Nevertheless, these data highlight the 55 importance of more Nab screening studies to predict shorter hospital stays. 56

57

58 Keywords: Neutralizing Antibodies; pseudovirus; SARS-CoV-2; HIV-1; PLWH;
 59 COVID-19

60

61 **1. Introduction**

The major portal of SARS-CoV-2 entry into host cells is through the respiratory tract, with the virus binding to the angiotensin-converting enzyme 2 (ACE-2) receptor on alveolar type 2 (AT2) cells in the epithelium. When attacked by the

virus, AT2 cells produce inflammatory mediators, stimulating proinflammatory 65 chemokine production and initiating immunoglobulin production (1). Generally, 66 immunoglobulin production occurs 4 days after the onset of symptoms, enabling 67 the diagnosis of COVID-19 through specific SARS-CoV-2 antibodies (2). The 68 detection of neutralizing antibodies (Nabs) against SARS-CoV-2 helps to 69 evaluate the status of the immune response of asymptomatic/symptomatic 70 COVID-19 patients and severe COVID-19, in addition to indicating protection 71 correlates (3). 72

Recent studies have demonstrated that the magnitude of Nab responses appears 73 74 to correlate with viral load, with higher responses reported among patients with more severe disease and older adults (4, 5). Several comorbidities, including 75 respiratory disease, hypertension, diabetes, kidney disease, and HIV-1 infection, 76 have been identified as risk factors associated with severe COVID-19 77 manifestation (6). Nonetheless, few studies describing the anti-SARS-CoV-2 Nab 78 response in HIV/COVID-19 coinfections have been performed thus far (7). The 79 identification and characterization of Nabs can help prevent new infections in 80 exposed individuals, and passive immunization can be used as a treatment 81 against disease progression to severe forms (8, 9). 82

The main objective of this study was to provide preliminary data on the Nab immune response to SARS-CoV-2 in a group of hospitalized subjects with COVID-19 in Rio de Janeiro, Brazil, including those with COVID-19 associated with HIV-1 infection. For this, we calculated the seroconversion rate of SARS-CoV-2 Nabs using the pseudovirus neutralization assay (PNA) (10) for a cohort of 103 hospitalized COVID-19 patients with or without HIV-1-associated infection and evaluated its association with clinical features of COVID-19.

90 **2. Materials and Methods**

91 Human samples

Plasma samples analyzed in this study were obtained from a clinical COVID-19 92 follow-up study that included moderate/severe hospitalized patients at the 93 COVID-19 Pandemic Hospital Center INI/FIOCRUZ, Rio de Janeiro, Brazil, 94 between June 2020 and May 2021 (RECOVER-SUS study-NCT04807699). A 95 total of 103 hospitalized participants who tested positive for SARS-CoV-2 by 96 nasopharyngeal sampling using RT-PCR were selected. Plasma samples were 97 collected on the first day of hospitalization (D1), after 14 days (D14), and between 98 99 seven and eleven months (D300) after hospital discharge. None of the patients were vaccinated for COVID-19 during the blood collection period. The local ethics 100 committee approved this study, and all participants signed an informed consent 101 102 form; all the samples were deidentified.

103 Cells

HEK293T-ACE2 and HEK293T/17 cells were cultured in DMEM with 10% fetal
bovine serum (FBS), 2 mM of L-glutamine, and 200 µg/mL of hygromycin B
(Thermo Fisher Scientific, US) at 37 °C with 5% CO₂. HEK293T-ACE2 cells were
a donation from BEI resources (BEI catalog number NR-52511), and the TZM-bl
cell line was obtained through the NIH AIDS Research and Reference Reagent
Program.

110 **Pseudovirus production and titration**

All transfections were performed in T75 culture flasks, and the pseudovirus was produced in HEK293T/17 cells cultured 24 hours before reaching 50%–70% confluence on the day of the experiment. Viral particles were produced using the Luciferase-IRES-ZsGreen backbone obtained from the BEI resource, which was

established by Crawford et al., 2020 (10). Briefly, 1 µg of HDM-IDTS pike-fixK 115 116 (BEI catalog number NR-52514), 6 µg of pHAGE-CMV-Luc2-IRES-ZsGreen-W (BEI catalog number NR-52516), 1.4 µg of HDM-Hgpm2 (BEI catalog number 117 NR-52517), 1.4 µg of HDM-tat1b (NR-52518) and 1.4 µg of pRC-CMV-Rev1b 118 (NR-52519) were used and cotransfected with Lipofectamine 3000 (Thermo 119 Fisher Scientific, US) and Opti-MEM I Reduced Serum Medium (Gibco) was 120 121 used, as well. For the positive control, VSV G-pseudotyped lentiviral particles with the ZsGreen backbone were produced using the plasmid pHEF expressing 122 vesicular stomatitis virus (VSV-G), obtained from the NIH-HIV Reagent Program 123 124 (catalog number RP-4693). Pseudovirus supernatants were collected approximately 72 h post-transfection, and the FBS concentration in the virus-125 containing culture medium was adjusted to 20% (i.e., for each 1 ml of virus 126 127 harvested, 0.125 ml of FBS was added), filtered through a 0.45-µm filter, and stored at -80 °C. 128

For median tissue culture infectious dose (TCID₅₀) assay measurements, 293T-129 ACE-2 cells (4 x 10⁴ cells in 100 μ L of growth medium/well) were added to each 130 well, followed by 20 mg/ml of DEAE-dextran with 11 pseudovirus dilutions, added 131 132 after 24 h. Serial 5-fold dilutions of pseudovirus were guadruplicated in 96-well culture plates in a volume of 100 µL of growth medium/well. After 48 h of 133 incubation (37 °C in 5% CO₂), 100 µL of culture medium was removed from each 134 well, and 100 µL of Britelite Plus Reagent (PerkinElmer) was added to the cells. 135 After 2 min of incubation at room temperature to allow cell lysis, 150 µL of the cell 136 lysate was transferred to black, solid 96-well plates for luminescence 137 measurements using a GloMax® Navigator Microplate Luminometer (Promega, 138 US). Wells with pseudovirus SARS-CoV-2-containing supernatant that was not 139

toxic to the cells based on light microscopy inspection, and that produced at least 140 relative luminescence units (RLU) 10 times greater than the background were 141 scored as positive. The TCID₅₀ was calculated using the Reed–Muench method 142 and using the macro described on the TCID₅₀; the cutoff macro is available on 143 HIV 144 the Los Alamos Immunology Database (https://www.hiv.lanl.gov/content/nab-reference-strains/html/home.htm). 145

146 **Pseudovirus Neutralization Assay**

Neutralization activity was expressed as Nab titers, defined as the interpolated 147 plasma dilution that produced a 50% reduction in virus infectivity or a 50% (ID₅₀) 148 149 and 90% inhibitory dose (ID₉₀), observed as reductions in Luciferase reporter gene expression after a single round of virus infection of 293T-ACE-2 cells, given 150 that some components essential for viral replication or persistent infection were 151 152 deleted from the genome. For each sample, residual infection was estimated across eight serum dilutions ranging from 1:20 to 1:4,3740; 3-fold serial dilutions 153 of samples were performed in duplicate (96-well flat bottom plate) in DMEM 154 growth medium (100 µL/well). An amount of virus to achieve a TCID₅₀ of 100 000 155 RLU equivalents was added to each well in a volume of 50 µL. The plates were 156 157 then incubated for 90 min at 37 °C in a total volume of 150 µL of growth medium. 293T-ACE-2 cells (4 x 10⁴ cells in 100 µL of growth medium) were added to each 158 well, and after 24 h, 20 mg/ml of DEAE-dextran was added. The normalized % 159 inhibition was calculated using uninfected cells (100% inhibition), and as a 160 negative control, we used prepandemic plasma (0% inhibition) as a reference. 161 For specificity, we used anti-SARS coronavirus recombinant human IgG1 (BEI 162 catalog number: NR-52392). After 48 h of incubation, 150 µL of culture medium 163 was removed from each well, and 100 μ L of Britelite reagent (PerkinElmer, US) 164

was added to the cells. After 2 min of incubation at room temperature to allow cell 165 lysis, 150 µL of the cell lysate was transferred to black, solid 96-well plates for 166 luminescence measurements using а GloMax® Navigator Microplate 167 Luminometer (Promega, US). The assays were evaluated as having passed 168 when the following parameters were met: the mean RLU of the virus control was 169 10 x higher than the background of the cell control; and the standard deviation of 170 RLU in the virus control well was 30%. All data were analyzed using Excel Macros 171 Nab analysis provided by the Global HIV Vaccine Enterprise, available on the Los 172 Alamos HIV Immunology Database (https://www.hiv.lanl.gov/content/nab-173 174 reference-strains/html/home.htm).

175 Statistical analysis

Nonparametric Mann–Whitney U tests were used to compare continuous 176 numerical baseline demographic and clinical variables, whereas Fisher's exact 177 tests were used for categorical variables. Multiple linear fixed effects models were 178 used to evaluate patient differences related to clinical outcome (discharge or 179 death) and HIV-1 serology. The model's fixed systematic component was 180 181 adjusted by confounding variables (age, sex, self-declared race, number of 182 comorbidities, and days since first symptoms of COVID-19 at hospital admission). The mean and 95% confidence intervals (95% CIs) were used, and the results 183 were also presented graphically for the estimated mean marginal effects, where 184 185 all other variables included in the multiple linear fixed models remained in equal proportions or their average values, and contrasts were constructed from these 186 estimated mean marginal effects. For each parameter (Figure 1), a 187 nonparametric ANOVA (Sidak's multiple comparisons test) was performed. 188 Tukey's honest significant difference (HSD) method was used to correct p values 189

by the number of comparisons whenever applicable (Figure 2). R software 190 191 (https://www.r-project.org/about.html) version 4.1.1 packages 'lme4', 'emmeans', and their dependencies were used to perform the statistical analyses. For each 192 parameter, a nonparametric ANOVA was performed, and a paired t test was 193 performed to compare Nab titers (Figures 3 and 4). To evaluate the continuous 194 ID_{50} and ID_{90} outcomes, we used a simple linear regression model assuming 195 normal distribution for these outcomes on the log scale. Statistical significance 196 was declared at a *p* value ≤0.05. Analysis was performed with statistical 197 computing software GraphPad Prism 9. 198

199 **3. Results**

3.1. Characteristics of the study population

Plasma samples from 103 hospitalized participants were analyzed for Nab 201 response to SARS-CoV-2. Sociodemographic and clinical data were collected for 202 the present study on the first day of hospital admission. Participants were 203 categorized according to the length of hospitalization into short hospitalization 204 (less than 14 days) and long hospitalization (over 14 days) groups to correlate 205 sociodemographic characteristics (Table 1) and clinical data (Table 2). Skin color, 206 207 age, and sex were not significantly distinct between the short and long hospitalization groups, but 71 (68.9%) participants self-declared that they had 208 brown skin. Most patients were male (57 (55.3%)), and the mean age was 57.27 209 210 (IQR=23.51) years (Table 1).

The most common symptoms observed were fever, cough, chest pain, coryza, dyspnea, anosmia, ageusia, diarrhea, abdominal pain, nausea, headache, myalgia, and oxygen saturation below 95%. The presence of these symptoms varied among the participants, with dyspnea symptoms being the most frequent

among the participants (74%), followed by oxygen saturation below 95% (37.5%) and myalgia (21%). We observed that most individuals required oxygen (80.6%) and remained hospitalized for longer periods, P < 0.01 (Table 2). Major comorbidities included hypertension (49 (47.1%)), diabetes mellitus (33 (31.7%)), and myalgia (22 (21.2%)). Other comorbidities were present in less than 20% of the participants.

Among the individuals included in this study, 15 (14.4%) tested positive for HIV-221 1 infection (PLWH). Of them, 9 (60%) were male, 14 (93.3%) self-declared having 222 brown skin, and none had obesity, anosmia, loss of taste, nausea, previous 223 224 stroke, heart failure, or coronary or rheumatic disease. Only 3 (20%) PLWH had systemic arterial hypertension (SAH), which was different from the group without 225 HIV infection, where the majority, 54.1%, had this comorbidity (P=0.02). The 226 mean age of patients hospitalized with COVID-19 was 57.27 years. However, 227 among PLWH/people with COVID-19, the mean age was 41.7 years (IQR=17.5), 228 and among those with only COVID-19, the mean age was 59.3 years (IQR=22; 229 *P*<0.01). 230

3.2 Early humoral immune responses among hospitalized patients with severe COVID-19

Humoral anti-SARS-CoV-2 immune responses were assessed at study entry for COVID-19 patients with severe disease. We noted variable levels of Nab anti-SARS-CoV-2 ID₅₀ in their plasma samples collected on the first day of hospitalization, corresponding to approximately nine days after the onset of the first symptoms. Two patients (1.9%) had very high titers of Nabs (ID₅₀) of 1:11,532 and 1:14,962, 17 (16.5%) had high neutralization titers, between 1:500 and 1:10,000 Nab ID₅₀, whereas 72 (70%) of the patients developed Nab titers between 1:500 and 1:20. Twelve patients (11.6%) had Nab titers under the detectable limit of the assay (<1:20). Therefore, approximately 88% of COVID-19 patients exhibited robust neutralization of SARS-CoV-2 PNA at hospitalization. Patients who had detectable production of Nabs were hospitalized on average for less time (17 days) than those who did not have detected Nabs (27 days), P=0.0363.

As expected, the VSV-G pseudotyped virus control showed the highest infectivity for all samples at a 1:20 dilution.

3.3 Association between anti-SARS-CoV-2 neutralizing antibodies and the

clinical condition of COVID-19 patients

Interestingly, we found that although the mean age of the patients included in this 250 study, we observed that 18 patients were between 18 and 39 years of age, and 251 of these, 13 (72%) were hospitalized for more than 14 days. The clinical aspects 252 of this youngest group with longer hospitalization were evaluated. Twelve 253 (92.3%) declared themselves as having black skin color, and none of them had 254 comorbidities such as stroke, cardiac insufficiency, coronary artery disease, 255 active cancer, chronic kidney disease or dialysis, rheumatic diseases, dementia, 256 obesity or previous bariatric surgery, hepatic cirrhosis or transplant. However, six 257 (46%) of them were PLWH, and one of them also had active tuberculosis. The 258 Nab geometric mean titer (GMT) ID₅₀ in this youngest group of patients 259 hospitalized for more than 14 days measured at study entry was 148 (95% CI: 260 56-387), while the GMT of young people hospitalized for less than 14 days was 261 360 (95% CI: 83-1,553). 262

263 Considering the COVID-19 discharge (n=69) or death (n=34) outcomes in our 264 study group, we observed that the GMT of anti-SARS-CoV-2 Nabs among

patients with a death outcome was 140 (95% CI: 74-263), whereas a Nab GMT 265 of 254 (95% CI: 170-380) was observed for those with a discharge outcome. 266 Hospitalization time was longer for patients who died (22; 95% CI: 15-29 days) 267 than for those who were discharged (16; 95% CI: 13-19 days), P=0.040. Of the 268 69 COVID-19 patients who were discharged, 7 (10%) had no Nab response on 269 D1 and were hospitalized for an average time of 20 (95% CI: 10-30) days. Of the 270 34 patients who died, 5 (14%) had no Nab on D1 and were hospitalized for an 271 average of 35 (95% CI: 13-58) days. 272

We further explored the clinical manifestations associated with the Nab (ID₅₀ and 273 274 ID₉₀) levels of the 103 hospitalized patients with COVID-19, and we did not identify any association between the production of Nab titers and the main 275 comorbidities such as arterial hypertension, diabetes, or obesity. However, 276 multivariate analysis showed that anosmia and ageusia (P<0.01) were 277 associated with higher Nab titers. All patients with anosmia or ageusia had 278 detectable Nab titers (Figure 1). The Nab GMT of patients who did not have 279 anosmia [32.2 (95% CI: 25-42)] or ageusia [31.7 (95% CI: 24-41)] was lower than 280 that of patients who had anosmia [123 (95% CI: 28-536)] or ageusia [187 (95% 281 282 CI: 40-869)].

To analyze other relevant clinical factors associated with Nabs, we investigated the hospitalization time in relation to initial Nab production on the first hospital day. We stratified the samples into two groups: 50 (48.6%) patients who stayed for up to 14 days and 53 (51.4%) patients who stayed for more than 14 days. We found significantly lower psV SARS-CoV-2 Nab ID₅₀ reciprocal plasma dilutions among patients hospitalized for more than 14 days (logFC=0.34; *P*=0.024) than among those with shorter hospitalization stays (Figure 2). The anti-SARS-CoV-2

Nab titer of patients with less than 14 days to hospital discharge [GMT=422 (95%
CI: 341-2014)] was significantly higher than that of patients with more than 14
days to hospital discharge [GMT=149 (95% CI: 32-1687)] (*P*<0.05).

To better understand the role of humoral immunity against SARS-CoV-2 infection, we analyzed the dynamics of changes in the Nab response initially at 14 days post-hospitalization (D14) compared to those obtained at hospital admission (D1). As shown in Figure 3A, plasma samples from D14 were available for 39 (73.5%) of the 53 patients who had longer hospital stays (>14 days). There was a significant increase (P=0.0190) in Nab titers (ID₅₀) between D1 [GMT=95 (95% CI: 57-158)] and D14 [GMT=251 (95% CI: 178-354)].

Patients who were discharged from the hospital were invited to return to the 300 INI/FIOCRUZ after seven months for a new blood collection and clinical follow-301 up. We performed the Nab assay at this point, hereby called D300, as it was the 302 average day after hospital admission. In this analysis, we compared the Nab titers 303 (ID₅₀) of D1 and D300 for the 60 patients who returned for the study, and we 304 observed an increased progression and persistence in the production of Nabs 305 306 among these SARS-CoV-2-infected and unvaccinated individuals. The GMT for 307 D1 was 136 (95% CI: 94-197), and the GMT for D300 was 219 (95% CI: 149-321) (P=0.0232) (Figure 3B). 308

309It was possible to compare D1, D14, and D300 for only 13 patients, and we310observed the following values of Nab D1 (ID_{50}) GMT=108 (95% CI: 44-266); Nab311D14 (ID_{50}) GMT=219 (95% CI: 120-400) and Nab D300 (ID_{50}) GMT=317 (95%312CI: 161-624), (P=0.0123 for D1 versus D300; P=0.0165 for D14 versus D300)313(Figure 3C).

Additionally, we evaluated the geometric mean titers of the anti-SARS-CoV-2 314 315 Nab ID₅₀ of the 15 COVID-19 patients living with HIV-1 (PLWH/COVID-19) included in our study group and compared it with HIV-negative COVID-19 316 patients. The PLWH/COVID-19 participants [(GMT=148 (95% CI: 54-407)] 317 showed no differences in anti-SARS-CoV-2 Nab production when compared to 318 individuals without HIV-1 infection (GMT=222 (95% CI: 153-321), P=0.950 319 (Figure 4). As a control, we also performed an HIV-1 PNA to determine the anti-320 HIV Nab titers of the PLWH/COVID-19 participants on antiretroviral therapy. A 321 high anti-HIV-1 antibody GMT of 583.9 (95% CI: 344-990) was detected, 322 323 demonstrating maintenance of anti-HIV-1 antibody production in individuals with HIV-1 hospitalized for COVID-19. 324

325 **4. Discussion**

Age is one of the most important prognostic factors associated with lethality in 326 SARS-CoV-2 infection (11). However, in our study, which included hospitalized 327 patients with moderate to severe COVID-19, age was not shown to be a 328 determining factor for the production or magnitude of anti-SARS-CoV-2 Nabs in 329 adults. In the population evaluated, we observed that 55% of those hospitalized 330 331 patients were men, the mean age was 57 years, and the mortality rate was 33%. The same was observed in the SIVEP-Gripe study, where 678,235 patients were 332 admitted to Brazilian hospitals and showed a mean age of 59 years and 35% 333 334 mortality (12). Perazzo et al., 2022, in a prospective multicenter study (RECOV-ER-SUS) that assessed hospital mortality, analyzed a cohort that included 1,589 335 participants and found that 54.5% of those admitted were men aged 62 and that 336 27.0% died during hospitalization (13). The sociodemographic characteristics of 337 the population of our study reflect the data presented by Zeiser et al., 2022 and 338

Perazzo et al., 2022, indicating a consensus on the profile of hospitalized patients
with COVID-19 in Brazil. Most men are aged between 50 and 60 years and have
approximately 30% mortality.

The most frequent comorbidities observed in our study were hypertension, 342 diabetes, and obesity. Hypertension is more frequent among elderly individuals 343 and subjects affected by other comorbidities (14). In a multivariate analysis after 344 adjustment for age and other cardiovascular risk factors, hypertension did not 345 play an independent role in COVID-19 development (15). Our study observed 346 similar anti-SARS-CoV-2 Nab titers between groups with and without these main 347 COVID-19 comorbidities. However, the survey by Karuna et al., 2021 noted that 348 hypertension was independently associated with low Nab titers (16). According 349 to some researchers, more than half of COVID-19 patients experienced 350 hyperglycemia, and approximately 33% developed diabetic ketoacidosis (17). 351 Marchand et al., 2020 were the first to observe an increased risk of type 1 352 diabetes development among patients with COVID-19 (18). In our study, the 353 proportion of diabetes patients was 31%, but the presence of diabetes was not 354 355 related to the ability to produce Nabs, similar to the results observed by Dispinseri 356 et al., 2021 (19).

We observed a correlation between anosmia and ageusia with high Nab titers. The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) released the COVID-19 Anosmia Reporting Tool for Clinicians, which revealed that anosmia was noted in 73% of COVID-19 cases and was the presenting symptom in 26.6% of cases (20). The incidence of anosmia among COVID-19 patients, however, varies in different studies. According to a meta-analysis by Tong et al., 2020, the prevalence of olfactory dysfunction among COVID-19

patients was estimated to be 52% (21). This variability could be due to genetic 364 factors, viral load (cases of viral damage), specificities of the different evaluated 365 populations, or antibody complexes. However, this last concept must be explored 366 since we found higher Nab titers among patients with anosmia. For example, 367 anosmia is one of the first clinical signs of some neurodegenerative diseases, 368 such as Parkinson's and Alzheimer's diseases. IgG deposits are found in 369 dopaminergic neurons in these patients, suggesting that neurons may be targets 370 for these immunoglobulins (22). In addition, changes in the blood-brain barrier 371 due to inflammation may facilitate the entry of IgG (23). Jae-Hoon Ko. et al. (2020) 372 373 evaluated 15 asymptomatic patients who presented only anosmia, and the production of Nabs was observed in 80.0% of patients (24). However, the 374 underlying biological basis of anosmia remains obscure, and our study has some 375 376 limitations. First, our cohort was limited to hospitalized patients, and the results could be different among people with SARS-CoV-2 infection with mild symptoms. 377 Most hospitalized patients had positive Nab titers (88%) with, on average, nine 378 days of symptoms. Other studies also observed the presence of antibodies in 379 acute infection, with a negativity range in 10-25% of patients (25, 26). Notably, 380 381 seven out of 12 (58%) recovered patients had Nab titers that were under the detectable level, suggesting that other immune responses may have contributed 382 to the recovery of these patients. Previous studies have suggested that cellular 383 384 immunity can mitigate severe infection, and T cells display strong cross-reactivity to SARS-CoV-2 (27). Whether these patients with COVID-19 without Nabs have 385 a high risk of rebound or reinfection or a poor response to vaccination should be 386 explored in further studies. Our data revealed that individuals who recovered from 387 COVID-19 experienced relatively robust antibody responses to SARS-CoV-2 388

PNA in the acute infection phase. However, patients who arrived at the COVID-19 hospital center with a moderate to critical condition and had low titers remained hospitalized for more than 14 days, and 92.5% needed ventilatory support. Therefore, contrary to what we expected, these patients who initially showed a low neutralizing response did not show milder clinical characteristics, such as the asymptomatic individuals with lower antibodies, as seen in other studies (28, 29).

Analysis of the humoral response across multiple cohorts of COVID-19 patients 396 showed that a natural SARS-CoV-2 infection can elicit Nabs in most cases, but 397 398 accumulating evidence indicates that the magnitude of the response varies greatly among individuals (30, 31). It is still unclear what interferes with the ability 399 to produce potent Nabs. However, it has been observed that plasmablast 400 expansion without somatic hypermutation during the acute phase of COVID-19 401 plays an important role in the early production of Nabs, which may reflect 402 preexisting B repertoire memory (32). 403

We observed that after 14 days of hospitalization, Nab GMTs increased in relation 404 to D1, as observed in other cohorts, where the kinetics of Nab induction were 405 406 reported to be similar for immunoglobulin seroconversion (31). Patients who died of COVID-19 were also able to increase antibody production at D14; however, 407 this delay in the initial immune response may have facilitated the expansion of 408 the viral load, leading to prolonged hospital stays and/or death. Some clinical 409 studies that have adopted the use of convalescent plasma or monoclonal 410 antibodies have observed patient improvement if administered at the beginning 411 of infection (33), and when the serum is administered late (28 days), there was 412 no improvement in the patient (34). The testing of Nabs in the acute phase of 413

414 COVID-19 can be a great ally for decision-making in clinical trials of convalescent 415 plasma administration as therapy. Another aspect that corroborates the use of 416 Nab identification and not just IgG titration is the presence of antibody-dependent 417 enhancement (ADE), which may be involved in the clinical observation of 418 increased severity of symptoms associated with early high levels of SARS-CoV-419 2 antibodies in patients (35).

The most extensive study on HIV/COVID-19 coinfection is from a Western Cape, 420 South Africa cohort. PLWH who contracted SARS-CoV-2 died at 2.39 times the 421 rate of patients without HIV with COVID-19. However, HIV was a minor risk factor 422 423 for severe COVID-19 compared with comorbidities such as cardiopulmonary diseases (36). In our analysis of the production ability of anti-HIV and anti-SARS-424 CoV-2 antibodies among coinfected patients, we did not observe differences in 425 relation to the mono-infected group (SARS-CoV-2), indicating that HIV-1 is not 426 an aggravating factor for COVID-19 in terms of humoral responsiveness, but we 427 also observed that a low titer of antibodies resulted in a longer hospitalization. 428 Mishra et al., 2021 observed that some HIV-1 Nabs recognize viral glycan shields 429 of SARS-CoV-2, showing cross-reactivity with SARS-CoV-2 (37). How much the 430 polyclonal cross-neutralizing antibody response can contribute to 431 the improvement of the patient has not yet been elucidated; however, in this study, 432 we verified that a potent neutralizing humoral response at the beginning of the 433 infection is associated with a faster recovery. 434

All protection mechanisms of COVID-19 are not yet clear; however, Nabs are considered a significant correlate of protective immunity and vaccine success, and it has been shown that the rate of SARS-CoV-2 infections among vaccinated individuals is lower among individuals with high Nab levels (38). Extensive efforts

to understand the relationship between SARS-CoV-2 and the immune system
have highlighted Nab detection assays as essential for screening for potent
antibodies for future immunotherapeutic designs. Here, we showed an important
relationship between the rapid production of Nabs and shorter hospital stays
among patients with moderate and severe COVID-19.

444

445 **Author Contributions**:

Conceptualization, DVA and MGM ; Data curation, MGM, MSBQ, MPR, SWC, 446 BGJG and VGSV; Formal analysis, DVA, MSBQ and MRA; Funding acquisition, 447 DVA, BGJG, VGSV and MGM; Investigation, DVA, LM, CBWG, FHC, MLG, JHP, 448 NBRS, MRA, LEC, KMG, MPR, SWC, BGJG, VGSV and MGM; Methodology, 449 DVA, PAC, TFBF, MGAS, CBWG, FHC, NBRS and ASC; Project administration, 450 451 DVA and MGM; Resources, LM, CBWG, FHC, MGM; Supervision, DVA, NBRS, CBWG, MGM, VGSV, BGJG; Visualization, PAC, TFBF, MGAS, JHP, ASC, LRG, 452 SWC, LEC, KMG, VGSV and MGM; Writing – original draft, DVA; Writing – 453 review & editing, MGM, CBWG, NDS, MSBQ, ASC, MRA. 454

455 **Funding:**

The study was supported by the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) (Grant numbers SEI-260003/013002/2021) and INOVA FIOCRUZ/Fundação Oswaldo Cruz (Grant numbers SEI-25380.001587/2020-20).

460 **Institutional Review Board Statement:**

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of National Institute of Infectology Evandro Chagas (INI)/ Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil, under the approval number CAAE 32449420.4.1001.5262. All participants or their
legal representatives signed an informed consent form prior to enrollment in the
study.

467 **Acknowledgments**:

The authors are thankful to all patients who agreed to participate in this study, the frontline health care workers at INI/FIOCRUZ Hospital, and the RECOVER study team in Rio de Janeiro. Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl Cells, ARP-8129, contributed by Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc."

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

479

480 **5. References:**

Tufa Abdisa, Gebremariam Tewodros Haile, Manyazewal Tsegahun, Getinet
 Tewodros, Webb Dominic-Luc, Hellström M, et al. Inflammatory mediators'
 profile in patients hospitalized with COVID-19: A comparative study 2022.
 Front. Immunol., 25 July 2022. Doi: 10.3389/fimmu.2022.964179.

Yin Shengxia, Tong Xin, Huang Aijun, Shen Han, Li Yang, Liu Yong, et al.
Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of
a COVID-19 patient. Journal of Infection 2020; 81(3): e31–2. Doi:
10.1016/j.jinf.2020.06.076.

489	3	Garcia-Beltran Wilfredo F., Lam Evan C., Astudillo Michael G., Yang Diane,
490		Miller Tyler E., Feldman Jared, et al. COVID-19-neutralizing antibodies
491		predict disease severity and survival. Cell 2021;184(2):476-488.e11. Doi:
492		10.1016/J.CELL.2020.12.015.
493	4	Robbiani Davide F., Gaebler Christian, Muecksch Frauke, Lorenzi Julio C.C.,

Wang Zijun, Cho Alice, et al. Convergent antibody responses to SARS-CoV2 in convalescent individuals. Nature 2020 584:7821 2020;584(7821):437–
42. Doi: 10.1038/s41586-020-2456-9.

Luo Huanle, Jia Tingting, Chen Jiamin, Zeng Shike, Qiu Zengzhao, Wu Shu,
et al. The Characterization of Disease Severity Associated IgG Subclasses
Response in COVID-19 Patients. Front Immunol 2021; 12:460. Doi:
10.3389/FIMMU.2021.632814/BIBTEX.

6 Richardson Safiya, Hirsch Jamie S., Narasimhan Mangala, Crawford James
M., McGinn Thomas, Davidson Karina W., et al. Presenting Characteristics,
Comorbidities, and Outcomes among 5700 Patients Hospitalized with
COVID-19 in the New York City Area. JAMA - Journal of the American
Medical Association 2020;323(20):2052–9. Doi: 10.1001/JAMA.2020.6775.

Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases South Africa, Boulle Andrew, Davies Mary-Ann, Hussey Hannah, Ismail Muzzammil, Morden Erna, et al. Risk
Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clinical Infectious Diseases 2021;73(7): e2005–15. Doi: 10.1093/CID/CIAA1198.

512 8 Deshpande Gururaj Rao, Sapkal Gajanan N., Tilekar Bipin N., Yadav Pragya
513 D., Gurav Yogesh, Gaikwad Shivshankar, et al. Neutralizing antibody

responses to SARS-CoV-2 in COVID-19 patients. Indian J Med Res
 2020;152(1 & 2):82–7. Doi: 10.4103/IJMR.IJMR 2382 20.

9 van de Veerdonk Frank L., Giamarellos-Bourboulis Evangelos, Pickkers
Peter, Derde Lennie, Leavis Helen, van Crevel Reinout, et al. A guide to
immunotherapy for COVID-19. Nat Med 2022;28(1):39–50. Doi:
10.1038/S41591-021-01643-9.

10 Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu 520 HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom 521 JD. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-522 523 CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020 May 524 6;12(5):513. doi: 10.3390/v12050513. PMID: 32384820; PMCID: PMC7291041. 525

11 Richardson Safiya, Hirsch Jamie S., Narasimhan Mangala, Crawford James
M., McGinn Thomas, Davidson Karina W., et al. Presenting Characteristics,
Comorbidities, and Outcomes Among 5700 Patients Hospitalized With
COVID-19 in the New York City Area. JAMA 2020; 323(20):2052–9. Doi:
10.1001/JAMA.2020.6775.

12 Zeiser Felipe André, Donida Bruna, da Costa Cristiano André, Ramos Gabriel 531 de Oliveira, Scherer Juliana Nichterwitz, Barcellos Nêmora Tregnago, et al. 532 First and second COVID-19 waves in Brazil: A cross-sectional study of 533 patients' characteristics related to hospitalization and in-hospital mortality. 534 Lancet Regional Health Americas 2022; 6:100107. Doi: 535 10.1016/J.LANA.2021.100107. 536

13 Perazzo Hugo, Cardoso Sandra W., Ribeiro Maria Pia D., Moreira Rodrigo,
 Coelho Lara E., Jalil Emilia M., et al. In-hospital mortality and severe

outcomes after hospital discharge due to COVID-19: A prospective
multicenter study from Brazil. Lancet Regional Health Americas 2022;
11:100244. Doi: 10.1016/J.LANA.2022.100244.

Farheen Saba, Agrawal Sudhanshu, Zubair Swaleha, Agrawal Anshu, Jamal
Fauzia, Altaf Ishrat, et al. Patho-Physiology of Aging and ImmuneSenescence: Possible Correlates With Comorbidity and Mortality in MiddleAged and Old COVID-19 Patients. Frontiers in Aging 2021; 2. Doi:
10.3389/FRAGI.2021.748591.

Iaccarino Guido, Grassi Guido, Borghi Claudio, Ferri Claudio, Salvetti
Massimo, Volpe Massimo M. Age and Multimorbidity Predict Death Among
COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of
Hypertension. Hypertension 2020; 76(2). Doi:
10.1161/HYPERTENSIONAHA.120.15324.

Karuna Shelly, Li Shuying Sue, Grant Shannon, Walsh Stephen R., Frank
Ian, Casapia Martin, et al. Neutralizing antibody responses over time in
demographically and clinically diverse individuals recovered from SARSCoV-2 infection in the United States and Peru: A cohort study. PLoS Med
2021;18(12). Doi: 10.1371/JOURNAL.PMED.1003868.

Thaweerat Wajana. Current evidence on pancreatic involvement in SARSCoV-2 infection. Pancreatology 2020;20(5):1013. Doi:
10.1016/J.PAN.2020.05.015.

Marchand Lucien, Pecquet Matthieu, Luyton Cédric. Type 1 diabetes onset
triggered by COVID-19. Acta Diabetol 2020;57(10):1265. Doi:
10.1007/S00592-020-01570-0.

Dispinseri Stefania, Lampasona Vito, Secchi Massimiliano, Cara Andrea,
Bazzigaluppi Elena, Negri Donatella, et al. Robust Neutralizing Antibodies to
SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19
Pneumonia. J Clin Endocrinol Metab 2021;106(5):1472–81. Doi:
10.1210/CLINEM/DGAB055.

- Kaye Rachel, Chang C. W.David, Kazahaya Ken, Brereton Jean, Denneny
 James C. COVID-19 Anosmia Reporting Tool: Initial Findings.
 Otolaryngology Head and Neck Surgery (United States) 2020; 163(1):132–
 4. Doi: 10.1177/0194599820922992.
- Tong Jane Y., Wong Amanda, Zhu Daniel, Fastenberg Judd H., Tham
 Tristan. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19
 Patients: A Systematic Review and Meta-analysis. Otolaryngol Head Neck
 Surg 2020; 163(1):3–11. Doi: 10.1177/0194599820926473.
- Doty Richard L., Hawkes Christopher H. Chemosensory dysfunction in
 neurodegenerative diseases. Handb Clin Neurol 2019;164:325–60. Doi:
 10.1016/B978-0-444-63855-7.00020-4.
- Erickson Michelle A., Banks William A. Neuroimmune Axes of the BloodBrain Barriers and Blood-Brain Interfaces: Bases for Physiological
 Regulation, Disease States, and Pharmacological Interventions. Pharmacol
 Rev 2018;70(2):278–314. Doi: 10.1124/PR.117.014647.
- 583 24 Ko Jae Hoon, Joo Eun Jeong, Park Su Jin, Baek Jin Yang, Kim Won Duk,
 584 Jee Jaehwan, et al. Neutralizing Antibody Production in Asymptomatic and
 585 Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients.
 586 J Clin Med 2020;9(7):1–13. Doi: 10.3390/JCM9072268.

587 25 Wang Hongye, Yan Dongshan, Li Ya, Gong Yanfei, Mai Yulin, Li Bingxiang,

588 et al. Clinical and antibody characteristics reveal diverse signatures of severe

and non-severe SARS-CoV-2 patients. Infect Dis Poverty 2022; 11(1):1–15.

590 Doi: 10.1186/S40249-022-00940-W/FIGURES/7.

- Wu Fan, Wang Aojie, Liu Mei, Wang Qimin, Chen Jun, Xia Shuai, et al.
 Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
 patient cohort and their implications. MedRxiv 2020:2020.03.30.20047365.
 Doi: 10.1101/2020.03.30.20047365.
- Ie Bert Nina, Tan Anthony T, Kunasegaran Kamini, Tham Christine Y L,
 Hafezi Morteza, Chia Adeline, et al. SARS-CoV-2-specific T cell immunity in
 cases of COVID-19 and SARS, and uninfected controls. Nature
 2020;584:457. Doi: 10.1038/s41586-020-2550-z.
- Brochot Etienne, Demey Baptiste, Touzé Antoine, Belouzard Sandrine,
 Dubuisson Jean, Schmit Jean-Luc, et al. Anti-Spike, anti-Nucleocapsid and
 neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers.

602 MedRxiv 2020:2020.05.12.20098236. Doi: 10.1101/2020.05.12.20098236.

603 29 Long Quan Xin, Tang Xiao Jun, Shi Qiu Lin, Li Qin, Deng Hai Jun, Yuan Jun,

604 et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2

605infections. Nature Medicine 2020 26:8 2020;26(8):1200-4. Doi:60610.1038/s41591-020-0965-6.

30 Dispinseri Stefania, Secchi Massimiliano, Pirillo Maria Franca, Tolazzi
Monica, Borghi Martina, Brigatti Cristina, et al. Neutralizing antibody
responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and
critical for survival. Nature Communications 2021 12:1 2021;12(1):1–12. Doi:
10.1038/s41467-021-22958-8.

G12 31 Cheng Meng Li, Liu Hui Ying, Zhao Hui, Wang Guo Qing, Zhou Chao, Zheng
Jing, et al. Longitudinal dynamics of antibody responses in recovered COVID19 patients. Signal Transduct Target Ther 2021; 6(1). Doi: 10.1038/S41392021-00559-7.
32 Unterman Avraham, Sumida Tomokazu S., Nouri Nima, Yan Xiting, Zhao
Amy Y., Gasque Victor, et al. Single-cell multi-omics reveals dyssynchrony
of the innate and adaptive immune system in progressive COVID-19. Nat

619 Commun 2022;13(1). Doi: 10.1038/S41467-021-27716-4.

33 Tiberghien Pierre, de Lamballerie Xavier, Morel Pascal, Gallian Pierre,
Lacombe Karine, Yazdanpanah Yazdan. Collecting and evaluating
convalescent plasma for COVID-19 treatment: why and how? Vox Sang
2020; 115(6):488–94. Doi: 10.1111/VOX.12926.

34 O'Donnell Max R., Grinsztejn Beatriz, Cummings Matthew J., Justman
Jessica E., Lamb Matthew R., Eckhardt Christina M., et al. A randomized
double-blind controlled trial of convalescent plasma in adults with severe
COVID-19. J Clin Invest 2021; 131(13). Doi: 10.1172/JCI150646.

35 Okuya Kosuke, Hattori Takanari, Saito Takeshi, Takadate Yoshihiro, Sasaki
Michihito, Furuyama Wakako, et al. Multiple Routes of Antibody-Dependent
Enhancement of SARS-CoV-2 Infection. Microbiol Spectr 2022; 10(2). Doi:
10.1128/SPECTRUM.01553-21.

36 Boulle Andrew, Davies Mary Ann, Hussey Hannah, Ismail Muzzammil,
Morden Erna, Vundle Ziyanda, et al. Risk Factors for Coronavirus Disease
2019 (COVID-19) Death in a Population Cohort Study from the Western Cape
Province, South Africa. Clin Infect Dis 2021;73(7): E2005–15. Doi:
10.1093/CID/CIAA1198.

637	37	Mishra N, Kumar S, Singh S, Bansal T, Jain N, Saluja S, Kumar R,
638		Bhattacharyya S, Palanichamy JK, Mir RA, Sinha S, Luthra K. Cross-
639		neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing
640		antibodies and polyclonal plasma. PLoS Pathog. 2021 Sep 24;17(9):
641		e1009958. doi: 10.1371/journal.ppat.1009958. PMID: 34559854; PMCID:
642		PMC8494312.
643	38	Plotkin Stanley A. Vaccines: correlates of vaccine-induced immunity. Clin
644		Infect Dis 2008;47(3):401–9. Doi: 10.1086/589862.

	Characteristics		P-		
	Characteristics	Overall	1-14	>14	value
Total		103 (100%)	50 (48.6%)	53 (51.4%)	
Gender	Male	57 (55.3%)	28 (56%)	29 (54.7%)	1
Gender	Female	46 (44.7%)	22 (44%)	24 (45.3%)	
	Brown	71 (68.9%)	30 (60%)	41 (77.4%)	0.032
Skin Color	White	14 (13.6%)	6 (12%)	8 (15.1%)	
	Black	8 (7.8%)	5 (10%)	3 (5.7%)	
	Unk	10 (9.7%)	9 (18%)	1 (1.9%)	
State of	RJ	101 (98.1%)	49 (98%)	52 (98.1%)	1
Origin	AM	2 (1.9%)	1 (2%)	1 (1.9%)	
	High school	42 (40.8%)	23 (46%)	19 (35.8%)	0.587
	Elementary School	20 (19.4%)	8 (16%)	12 (22.6%)	
Schooling	University Education	8 (7.8%)	4 (8%)	4 (7.5%)	
	First grade	22 (21.4%)	10 (20%)	12 (22.6%)	
	Illiterate	11 (10.6%)	5 (10%)	6 (11.5%)	
Age		57.27	56.37	57.57	0.847
Age		(IQR=23.51)	(IQR=23.59)	(IQR=25.39)	
	18-39	18 (17.4%)	5 (10%)	13 (24.5%)	0.045
Age	40-59	34 (33%)	21 (42%)	13 (24.5%)	
Category	60-79	45 (43.7%)	23 (46%)	22 (41.5%)	
	80-90	6 (5.9%)	1 (2%)	5 (9.5%)	

Table 1. Sociodemographic characteristics of study participants.

647 Values are presented as number (%) or median (interquartile range).

648

649

Comorbidities	Levels	Overall	Hospita	<i>P</i> -value	
			1-14 days	>14 days	
Systemic arterial	No	54 (52.4%)	24 (48%)	30 (56.6%)	0.499
hypertension	Yes	49 (47.6%)	26 (52%)	23 (43.4%)	
Diabetes mellitus	No	70 (68%)	31 (62%)	39 (73.6%)	0.295
Diabeteo memitas	Yes	33 (32%)	19 (38%)	14 (26.4%)	
Chronic obstructive	No	93 (90.3%)	48 (96%)	45 (84.9%)	0.117
pulmonary disease	Yes	10 (9.7%)	2 (4%)	8 (15.1%)	
Cerebrovascular	No	101 (98.1%)	50 (100%)	51 (96.2%)	0.501
accident	Yes	2 (1.9%)	0 (0%)	2 (3.8%)	
Cardiovascular	No	99 (96.1%)	48 (96%)	51 (96.2%)	1
failure	Yes	4 (3.9%)	2 (4%)	2 (3.8%)	
Coronary heart	No	102 (99%)	49 (98%)	53 (100%)	0.977
disease	Yes	1 (1%)	1 (2%)	0 (0%)	
Active cancer	No	103 (100%)	50 (100%)	53 (100%)	0.768
Chronic Kidnev	No	102 (99%)	50 (100%)	52 (98.1%)	1
Disease (on dialysis)	Yes	1 (1%)	0 (0%)	1 (1.9%)	
	No	102 (99%)	49 (98%)	53 (100%)	0.977
Rheumatic Diseases	Yes	1 (1%)	1 (2%)	0 (0%)	01777
	No	102 (99%)	50 (100%)	52 (98 1%)	1
Dementia	Yes	1 (1%)	0 (0%)	1 (1 9%)	1
Obesity or previous	No	84 (81.6%)	41 (82%)	43 (81 1%)	1
bariatric surgery	Vos	19 (18 4%)	9 (18%)	10 (18 9%)	1
ballatile surgery	No	96 (02 2%)	/0 (08%)	10 (10.276)	0 127
Current smoking	Vos	7 (6.8%)	$\frac{49}{1}$ (2%)	47 (00.770) 6 (11.3%)	0.157
	No	7(0.070)	1(2/0)	51(06.2%)	1
Active tuberculosis	INO	99 (96.1%)	40(96%)	31(90.2%)	1
	res	4 (3.9%)	2 (4%)	2(3.8%)	0.077
Tuberculosis treated	INO	102 (99%)	49 (98%)	53 (100%)	0.977
	Yes	1 (1%)	1 (2%)	0 (0%)	4
Hepatic cirrhosis	No	102 (99%)	50 (100%)	52 (98.1%)	1
-	Yes	1 (1%)	0 (0%)	1 (1.9%)	
Transplant	No	103 (100%)	50 (100%)	53 (100%)	0.768
HIV serological	Negative	88 (85.4%)	45 (90%)	43 (81.1%)	0.101
status	Positive	15 (14.6%)	5 (10%)	10 (18.9%)	
Clinical data during COVID-19					
E	No	51 (49.5%)	26 (52%)	25 (47.2%)	0.77
Fever	Yes	52 (50.5%)	24 (48%)	28 (52.8%)	
Oxygen Saturation	No	63 (61.2%)	33 (66%)	30 (56.6%)	0.438
Below 95 %	Yes	40 (38.8%)	17 (34%)	23 (43.4%)	
c 1	No	40 (38.8%)	19 (38%)	21 (39.6%)	1
Cough	Yes	63 (61.2%)	31 (62%)	32 (60.4%)	
	No	99 (96.1%)	48 (96%)	51 (96.2%)	1
Chest Pain	Yes	4 (3.9%)	2 (4%)	2 (3.8%)	
	No	97 (94.2%)	47 (94%)	50 (94.3%)	1
Coryza	Yes	6 (5.8%)	3 (6%)	3 (5.7%)	-
	No	26 (25.2%)	14 (28%)	12 (22.6%)	
Dyspnea	Yes	77 (74.8%)	36 (72%)	41 (77.4%)	0.69
Odynophagy	No	103 (100%)	50 (100%)	53 (100%)	0.768
Anosmia	No	95 (92.2%)	45 (90%)	50 (94.3%)	0.65
		/ - / - /			0.00

651	Table 2.	Clinical	characteristics	and sy	mptoms	of study	participants

Odynophagy	Yes	8 (7.8%)	5 (10%)	3 (5.7%)	
A	No	96 (93.2%)	47 (94%)	49 (92.5%)	1
Ageusia	Yes	7 (6.8%)	3 (6%)	4 (7.5%)	
Diamhas	No	95 (92.2%)	46 (92%)	49 (92.5%)	1
Diarrnea	Yes	8 (7.8%)	4 (8%)	4 (7.5%)	
Abdominal Dain	No	100 (97.1%)	49 (98%)	51 (96.2%)	1
Addominal Pain	Yes	3 (2.9%)	1 (2%)	2 (3.8%)	
Neurose	No	99 (96.1%)	49 (98%)	50 (94.3%)	0.652
Nausea	Yes	4 (3.9%)	1 (2%)	3 (5.7%)	
Haadaaba	No	92 (89.3%)	45 (90%)	47 (88.7%)	1
пеацасне	Yes	11 (10.7%)	5 (10%)	6 (11.3%)	
Mualaia	No	82 (79.6%)	39 (78%)	43 (81.1%)	0.881
Niyaigia	Yes	21 (20.4%)	11 (22%)	10 (18.9%)	
Some Thrombosis	No	103 (100%)	50 (100%)	53 (100%)	0.768
Oxygen	No	20 (19.4%)	16 (32%)	4 (7.5%)	0.004
Supplementation or					
Ventilatory Support	Yes	83 (80.6%)	34 (68%)	49 (92.5%)	
WHO Clinical	WHO				
Progression Scale	Scale	8 (IQR=0)	8 (IQR=0)	8 (IQR=0)	0.511
Classory Cools	Glasgow				
Glasgow Scale	Scale	15 (IQR=0)	15 (IQR=0)	15 (IQR=0)	0.321
SOFA	SOFA	3 (IQR=4)	2.5 (IQR=3)	5 (IQR=5)	0.01
SAPS3	SAPS3	48 (IQR=19)	45 (IQR=17)	49 (IQR=15)	0.048
Outcome	Discharge	69 (67%)	37 (74%)	32 (60.4%)	0.208
	Death	34 (33%)	13 (26%)	21 (39.6%)	

652 Values are presented as number (%) or median (interquartile range).



654

655

Figure 1: Clinical symptoms of anomia and ageusia of SARS-CoV-2 infection are influenced by neutralizing antibody titers. The COVID-19 patients (n = 103) were divided into groups according to the presence or absence of these symptoms and analyzed for their Nab titers with 90% inhibition (ID₉₀). The bar line represents the geometric mean with a 95% confidence interval. For each parameter, a nonparametric ANOVA (Sidak's multiple comparisons test) was performed; statistical significance is indicated with the following notation: *P*<0.001.



665

Figure 2: PsV SARS-CoV-2 neutralizing antibody ID₅₀ reciprocal plasma dilutions 666 and hospitalization stay (in days). The sample distributions of data are 667 represented in box plots and strip plots in gray. In black, the center circle 668 represents the expected mean marginal effect for each group estimated from 669 linear multiple fixed effects models. The fixed effects were adjusted by age, sex, 670 self-declared race, number of comorbidities, and days since the first symptoms 671 of COVID-19 at hospital admission. Black horizontal bars represent the 95% 672 confidence intervals of the expected mean marginal effects by group. 673 674

675 **(a)**







(b)





(c)



680

Figure 3: Longitudinal humoral immune response of inpatients with COVID-19. A, 681 Nabs (ID₅₀) of COVID-19 patients at admission D1 compared to the Nab (ID₅₀) 682 assessment 14 days after hospital discharge. B, Nabs (ID₅₀) of COVID-19 683 patients at admission D1 compared to Nab (ID₅₀) assessment 300 days after 684 hospital discharge. C, Changes in Nab titers (ID₅₀) for each patient are shown 685 over time. Data from patients for the first sample D1, after 14 days and the last 686 collected sample D300 are shown. 687



689

Figure 4: Neutralizing antibody responses from SARS-CoV-2-infected and HIVcoinfected patients. Nabs during the first day of hospitalization of 85 COVID-19 patients not infected with HIV and 15 PLWH coinfected with SARS-CoV-2 (COVID-19/PLWH) are shown. Fifteen patients (COVID-19/PLWH) showed Nab titers against SARS-CoV-2 and HIV-1 pseudovirus. Negative values (titers below 20) were considered 10 for calculating the geometric mean titer (GMT). The horizontal bars indicate the GMT, and the bars indicate 95% confidence intervals.